Development of High Affinity Camptothecin-Bombesin Conjugates That Have Targeted Cytotoxicity for Bombesin Receptor-containing Tumor Cells
Open Access
- 1 May 2004
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (22) , 23580-23589
- https://doi.org/10.1074/jbc.m401938200
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesinLife Sciences, 2003
- An adjustable release rate linking strategy for cytotoxin–Peptide conjugatesBioorganic & Medicinal Chemistry Letters, 2003
- Neuropeptides as Autocrine Growth Factors in Cancer CellsCurrent Pharmaceutical Design, 2003
- Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cellsNuclear Medicine and Biology, 2001
- Peptides as Carrier for Tumor Diagnosis and TreatmentCurrent Medicinal Chemistry - Anti-Cancer Agents, 2001
- Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugsPharmacology & Therapeutics, 1999
- Identification of a unique ligand which has high affinity for all four bombesin receptor subtypesEuropean Journal of Pharmacology, 1998
- Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin ReceptorsJournal of Biological Chemistry, 1997
- GRP receptors are present in non small cell lung cancer cellsJournal of Cellular Biochemistry, 1996